NOTICES ISSUED TO 263 PHARMACEUTICAL COMPANIES FOR OVERCHARGING IN FY16

New Delhi, Medicare News, May 15, 2016
The National Pharmaceutical Pricing Authority (NPPA) has issued notices to 263 firms that were found overcharging during 2015-16, Parliament was informed on Tuesday.

NPPA has informed that during 2015-16, demand notices were issued to 263 companies amounting to Rs 928.32 crore, Minster of Chemicals & Fertilizers Ananth Kumar said in a reply in Lok Sabha. The recovery effected is Rs 12.68 crore, he added.

“Whenever companies are found overcharging the consumer in respect to price of medicines, NPPA issues demand notices for recovery of overcharged amount along with interest thereon under various provisions of DPCO 1995 and DPCO 2013…,” Kumar said.

NPPA is mandated to fix and revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.
It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers. Besides, it monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

Related Posts

Centre Pushes Haryana to Fast-Track AIIMS Rewari

New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

Rajasthan Drops 1,114 Hospitals From RGHS in Fraud Drive

Jaipur, August 18, 2025 — Rajasthan has removed 1,114 private hospitals from the Rajasthan Government Health Scheme (RGHS) after a statewide fraud sweep. The Health Department also suspended 1,901 healthcare…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’